744256-69-7

Usage

Uses

Used in Pharmaceutical Research and Development:
Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (aS)-, benzenesulfonate is used as a research compound for its potential anti-inflammatory and analgesic properties. Its inhibitory activity against cyclooxygenase-2 makes it a valuable asset in the development of new drugs aimed at treating inflammatory conditions and pain.
Used in Drug Synthesis:
In the pharmaceutical industry, Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (aS)-, benzenesulfonate serves as a key intermediate in the synthesis of drugs targeting inflammation and pain. Its unique structure and biological activity provide a foundation for creating novel therapeutic agents with improved efficacy and reduced side effects.
Used in Experimental Medicine:
The benzenesulfonate salt form of Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (aS)is utilized in experimental medicine to study the mechanisms of action and potential therapeutic effects in various inflammatory and painful conditions. This helps in understanding its role in modulating the inflammatory process and managing pain.
Used in Drug Delivery Systems:
As part of drug delivery research, Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (aS)-, benzenesulfonate may be explored for its potential to improve the bioavailability and targeting of anti-inflammatory and analgesic drugs, enhancing their therapeutic outcomes and patient compliance.

Upstream product

• 90055-48-4 clopidogrel 
• 28783-41-7 6,7-dihydro-4H-thieno[3,2-c]pyridine hydrochloride 
• 98-11-3 benzenesulfonic acid 
• 120202-66-6 (S)-(+)-clopidogrel bisulfate 
• 223123-46-4 methyl (R)-2-(2-chlorophenyl)-2-benzenesulfonyloxyacetate 
• 113665-84-2 (S)-(+)-clopidogrel 

Relevant academic research and scientific papers

Preparation method of high-purity clopidogrel

The invention relates to a preparation method of high-purity clopidogrel (formula I). The preparation method comprises the following steps: firstly, performing reaction on a compound as shown in formula II and a compound as shown in formula III in an acetone solvent under the existence of alkali, filtering reactants to remove insolubles, and adding sulfuric acid into filtrate for separation and crystallization, thus obtaining clopidogrel disulfate with the optical purity of 98 percent or above; neutralizing the clopidogrel disulfate with inorganic alkali in dichloromethane and water, obtaining clopidogrel free alkali, salifying the clopidogrel free alkali and benzenesulfonic acid in an alcohol solvent, then adding an alkane solvent for separation and crystallization, thus obtaining clopidogrel benzene sulfonate (formula V) with the optical purity of 99.9 or above, and applying the clopidogrel benzene sulfonate to a medicine preparation, or neutralizing the clopidogrel disulfate with the inorganic alkali in the dichloromethane and the water, thus obtaining the clopidogrel free alkali with the optical purity of 99.9 percent, and applying the clopidogrel free alkali to preparation of pharmaceutically acceptable salt and a medicine preparation.

A benzene sulfonic acid Clopidogrel crystal form III method

The invention discloses a method of preparing a benzene sulfonic acid clopidogrel crystal form III. The method comprises the steps of: (a) dissolving (S)-(+)-clopidogrel alkali in a ketone solvent; (b) cooling an obtained mixture, adding water-containing

HIGHLY PURE SALTS OF CLOPIDOGREL FREE OF GENOTOXIC IMPURITIES

The present invention relates to substantially pure salts of clopidogrel of Formula (I) substantially free from genotoxic impurities. (I) wherein (S) represents a suitable organic or inorganic acid, which forms a salt with clopidogrel having less acidity.

PROCESSES FOR THE PREPARATION OF DIFFERENT FORMS OF (S)-(+)-CLOPIDOGREL BESYLATE

Disclosed herein are the improved processes for the preparation of different forms of (S)-(+)-Clopidogrel besylate, pharmaceutical compositions containing them and their use in medicine.

Pharmaceutical formulations comprising clopidogrel

The formation of melt granulates comprising the drug clopidogrel of the following formula or a pharmaceutically acceptable salt thereof markedly reduces degradation of clopidogrel and its salts on storage.

PROCESSES FOR THE PREPARATION OF DIFFERENT FORMS OF (S)-(+)-CLOPIDOGREL BESYLATE

Disclosed herein are the improved processes for the preparation of different forms of (S)-(+)-Clopidogrel besylate, pharmaceutical compositions containing them and their use in medicine.

Pharmacologically Acceptable Salts of Clopidogrel

The invention relates to polymorphous forms of (+)-(S)-clopidogrel hydrogen bromide, described as polymorphous “form A”, polymorphous “form B”, polymorphous “form C”, polymorphous “form D”, polymorphous “form E”, and polymorphous “form F”, in addition to

Benzenesulfonic acid salts of clopidogrel, methods for preparing same, and pharmaceutical formulations thereof

The present invention relates to benzenesulfonic acid salts of clopidogrel, including crystalline clopidogrel besylate in form III, processes for the preparation of these salts, the use of these salts for producing pharmaceutical formulations, and to pharmaceutical compositions comprising these salts.

SALT OF BENZOSULFONIC ACID CONTAINING CLOPIDOGREL AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL FORMULATIONS

The invention relates to the salt of benzosulfonic acid containing clopidogrel and pharmaceutical formulations comprising said salt.

SALTS OF CLOPIDOGREL AND PROCESS FOR PREPARATION

Disclosed are new salts of Clopidogrel viz. Clopidogrel mesylate, Clopidogrel besylate and Clopidogrel tosylate, methods for their preparation and pharmaceutical compositions containing them and their use in medicine.